-
Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations
12 Apr 2023 17:00 GMT
… open non-comparative trial of 83 patients … , respectively, both stating insufficient evidence to recommend … treatment.107 Currently available drugs originate from three drug … 2023.
49. European Medicines Agency, Cancidas. EPAR-product information; …
-
Global Geriatric Medicines Market to Witness Positive Growth of 6% Through 2026
11 Jun 2021 00:46 GMT
… hospital visits for treatment of various chronic … in clinical trials to develop critical drug formulations which … Pharmaceutica Ltd. for marketing CRESEMBA, an anti-fungal medicine … products ranging from internal medicines, vaccines, oncology and rare diseases …
-
Cidara’s Drug Candidate Meets Clinical Trial Objectives
01 Aug 2019 01:25 GMT
… trials this spring.
“There have been no new drugs approved for the treatment … ’s drug cancidas in 91 patients. Midway through the trial pivoted … CEO of the San Diego biotech.
Cidara needs strong phase … model that will pay pharmaceutical companies up front for …
-
Global Antifungal Drugs Market To Reach USD 13.03 Billion By 2026 | Reports And Data
13 May 2019 15:29 GMT
… would require proper medication for their cure. … counter) antifungal drugs especially for treatment for skin related … ., Bayer AG, Enzon Pharmaceuticals Inc., GlaxoSmithKline PLC, … CRESEMBA)
Others
Echinacandins Caspofungin (Cancidas)
Micafungin (Mycamine/ …
-
Global $12.7 Bn Antifungal Drugs (Azoles, Echinocandins, Polyenes, Allyamines) Market 2018-2025 - Rising R&D Pertaining to the Development of Novel Drugs
18 Feb 2019 12:00 GMT
… agreements in the pharmaceutical industry for development … 2397, an antifungal drug for the treatment of pulmonary aspergillus … 4.3.2 Caspofungin (Cancidas)
4.3.3 Micafungin … GlaxoSmithKline plc
Abbott
Glenmark
Enzon Pharmaceuticals, Inc.
Astellas Pharma, …
-
Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Candidiasis;Aspergillosis, Date of authorisation: 23/10/2001, Revision: 32, Status: Authorised
17 Sep 2018 12:07 GMT
Studies show that Cancidas treatment can lead to favourable … respond to other treatments, 36% responded to Cancidas (19 out of … not tolerate other treatments, 70% responded to Cancidas (7 out of … who were treated empirically, Cancidas was as effective as …
-
Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Candidiasis;Aspergillosis, Date of authorisation: 23/10/2001, Revision: 32, Status: Authorised
17 Sep 2018 12:07 GMT
Studies show that Cancidas treatment can lead to favourable … respond to other treatments, 36% responded to Cancidas (19 out of … not tolerate other treatments, 70% responded to Cancidas (7 out of … who were treated empirically, Cancidas was as effective as …
-
Competitive Pressure And Lower Demand Will Likely Weigh On Merck’s Anti-Infective Drugs Portfolio
22 May 2018 15:54 GMT
… pharmaceutical companies, and loss of patent exclusivity for some of the drugs … Gardasil an important vaccine. The drug’s revenues have … by the FDA in early 2016 for the treatment of … in other markets.
Among other drugs, Cancidas, Primaxin, Cubicin, Ivanz, …
-
Why Anti-Infective Drugs Account For A Third of Merck’s Valuation
03 Jan 2018 15:12 GMT
… more detail.
Anti-Infective Drugs Will Likely Account For … in 2018. However, other drugs – including Cancidas, Primaxin, Cubicin, Ivanz … two more anti-infective drugs will lose their patent … of Merck’s anti infective drugs, including Isentress, are …
-
Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2007-2012
18 Sep 2024 16:26 GMT
Drug
Sponsor
Medical Review
Clinical Pharmacology Review
Statistical … -435KB)
BPCA
Caspofungin acetate - Cancidas
Merck
Medical (PDF -3MB)
Clinical pharmacology … System - Daytrana
Shire Pharmaceuticals
Medical (PDF -2MB)
Medical (PDF -36KB)
Clinical …
About
© 1995-2025